Menu

Sodium Alginate

Also known as: E401, Alginic acid sodium salt

A brown-seaweed hydrocolloid whose food texture role and finished reflux formulations require different kinds of evidence.

A muted green monoprint of a brown-seaweed frond with a translucent gel-like brush mark on cream paper.
Editorial illustration

Sodium alginate is a brown-seaweed-derived polymer used for texture and stabilization. Alginate-containing reflux medicines are a separate application: trials evaluate finished formulations, often with antacid components. Reviews differ, so neither a food thickener label nor an isolated powder establishes a reliable replacement for acid-suppressing treatment.1, 2, 3

  • U.S. food permission has food-category-specific concentration limits, not an unlimited-use instruction.1
  • The 2017 review pooled 14 studies with 2,095 participants and favored alginate-containing products over placebo or antacids, with substantial heterogeneity.2
  • The 2020 review did not find clear pooled superiority for several symptom comparisons or a convincing add-on benefit to PPIs.3

What is Sodium Alginate?

The U.S. rule identifies the sodium salt of alginic acid, a natural brown-algae polyuronide. Carrageenan is a different hydrocolloid, not an alternative name. The ingredient list tells you a material is present; the complete formula and intended use determine which evidence is relevant.1, 4

Where it comes from

Natural sources

  • Alginic acid extracted from brown algae.

How it's made

The purified acid is converted to its sodium salt; specifications matter beyond the source seaweed.

What it does in products

  • Food thickener and stabilizer within permitted uses
  • Formulation or firming aid
  • Component of finished raft-forming reflux formulations

Benefits

Reflux symptom relief depends on the finished formulation

limited evidence

There is clinical evidence for some alginate-containing preparations, but it is not uniform across comparisons.2, 3

The favorable 2017 pooled result and the more mixed 2020 findings used different study sets and symptom analyses. An insignificant comparison with a PPI is not proof of equal efficacy. Neither review establishes that food-grade alginate alone reproduces a combination medicine.

Evidence scope and limitations

Sodium alginate's U.S. food identity and technical uses, adult reflux-formulation reviews, and one explicitly UK combination leaflet as a formulation/safety example.

  • Evidence on mixtures cannot isolate every contribution of sodium alginate or establish equivalence of different products.
  • The cited reviews differ; long-term safety, pediatric treatment and replacement of prescribed care are not established here.
  • The UK leaflet is not a U.S. approval, a product endorsement or a universal dose/interaction schedule.

Evidence last checked: 2026-10-23

Side effects & safety

Digestive symptoms or hypersensitivity to a finished medicine (varies)The cited UK combination leaflet lists uncommon diarrhea, nausea or vomiting and rare allergic reactions. These are product-level observations, not isolated-alginate incidence estimates.

Safety considerations

  • The UK leaflet advises spacing that combination medicine from other oral medicines; consult the actual local label and a pharmacist rather than applying one schedule to every alginate product.
  • Not for: Kidney disease or sodium/potassium dietary restrictions require attention to the complete formula, not just the alginate amount.
  • Not for: An adult formulation is not automatically suitable for infants. Persistent symptoms need assessment; the cited leaflet specifies medical follow-up after seven days.
4, 3

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In finished reflux formulations

For formulation context, the cited UK chewable tablet contains 500 mg sodium alginate plus 100 mg potassium bicarbonate per tablet. This is not a universal research dose, a recommendation for U.S. readers or a recipe for mixing powder at home. Follow the actual licensed product's instructions and age limits.

4

Regulatory status

  • 21 CFR 184.1724 addresses sodium alginate as a food ingredient under defined technical uses and limits. It does not authorize all reflux claims or make a UK medicine label applicable in the United States. Therapeutic intended uses raise separate drug-regulatory questions.
  • GRAS (generally recognized as safe) for food use.
1, 5

The word alginate is not the whole formula

A food system needs a texture ingredient; a reflux study tests a preparation with a particular composition. Those are not the same experiment. Review the additional actives and the comparator before transferring a result to another bottle, tablet or powder.

For an add-on claim, the useful question is whether the complete alginate preparation improved symptoms beyond the existing PPI, not whether its physical barrier mechanism sounds plausible. The conflicting pooled findings leave that promise uncertain.

1, 2, 3, 4

Frequently asked questions

Does permitted food use prove a reflux remedy works?

No. Food-use conditions establish a different regulatory context. Symptom benefits require evidence for the relevant finished preparation, and do not follow from the seaweed source or thickening function alone.1, 2, 3

The bottom line

Match the evidence to the complete formulation and the intended use, not just the shared polymer name.

References

  1. 21 CFR 184.1724: Sodium alginate. Electronic Code of Federal Regulations · government guidance · Current identity, permitted technical functions and food-category-specific limits checked October 23, 2026
  2. Leiman DA, Riff BP, Morgan S, et al.. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Diseases of the Esophagus (2017) · systematic review · PMID 28375448; DOI 10.1093/dote/dow020; primary abstract checked; alginate-containing compounds, not isolated powder
  3. Zhao CX, Wang JW, Gong M. Efficacy and safety of alginate formulations in patients with gastroesophageal reflux disease: a systematic review and meta-analysis of randomized controlled trials. European Review for Medical and Pharmacological Sciences (2020) · systematic review · PMID 33275256; DOI 10.26355/eurrev_202011_23841; indexed primary abstract checked after live retrieval failed
  4. Gaviscon Advance Mint Chewable Tablets: Patient Information Leaflet. Reckitt Benckiser Healthcare (UK) Ltd / electronic Medicines Compendium (2025) · ingredient monograph · UK manufacturer leaflet; text revised November 2025; composition, warnings and seven-day follow-up checked; not a U.S. authorization or product recommendation
  5. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?). U.S. Food and Drug Administration · government guidance · Undated agency resource; intended-use and toothpaste cosmetic/drug distinctions checked October 23, 2026

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.